MARKET

SWTX

SWTX

SPRINGWORKS THERAPEUTICS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

67.08
+0.48
+0.72%
Opening 10:24 12/02 EST
OPEN
66.17
PREV CLOSE
66.60
HIGH
67.08
LOW
63.41
VOLUME
16.50K
TURNOVER
--
52 WEEK HIGH
71.15
52 WEEK LOW
19.50
MARKET CAP
3.27B
P/E (TTM)
-38.8419
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
SpringWorks Therapeutics to Participate in the Evercore ISI HealthCONx Conference
STAMFORD, Conn., Nov. 24, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will participate in a Fireside Chat at the 3rd Annual Evercore ISI HealthCONx Conference, taking place virtually on Wednesday, December 2, 2020 at 12:35 p.m. ET. A video webcast will be available on the “Events & Presentations” page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.About SpringWorks Therapeutics SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio. For more information, visit www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn.Contact: Kim Diamond Phone: 203-561-1646 Email: kdiamond@springworkstx.com
GlobeNewswire · 11/24 11:30
The Daily Biotech Pulse:Kazia Jumps On Data Readout, Clinical Hold On Cellectis' Blood Cancer Study Lifted
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 17)
Benzinga · 11/18 12:29
SpringWorks Therapeutics Q3 EPS $(0.51) Up From $(1.77) YoY
SpringWorks Therapeutics (NASDAQ:SWTX) reported quarterly losses of $(0.51) per share. This is a 71.19 percent increase over losses of $(1.77) per share from the same period last year.
Benzinga · 11/12 12:26
Jazz Pharmaceuticals acquires SpringWorks Therapeutics' FAAH inhibitor program
Jazz Pharmaceuticals ([[JAZZ]] -0.6%) and SpringWorks Therapeutics ([[SWTX]] +0.7%) entered into an asset purchase and exclusive license agreement wherein the former has acquired the latter's fatty acid amide hydrolase ((FAAH))
Seekingalpha · 10/26 12:06
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) ("SpringWorks") today announced that Jazz Pharmaceuticals Ireland Limited ("Jazz") and SpringWorks have entered into an asset purchase and exclusive license agreement under which Jazz has acquired SpringWorks' fatty acid amide hydrolase ("FAAH") inhibitor program including PF-04457845. Jazz will initially focus on developing PF-04457845 for the potential treatment of post-traumatic stress disorder ("PTSD") and associated symptoms.
PR Newswire · 10/26 11:30
The Daily Biotech Pulse: Vertex Pulls Plug On Protein Deficiency Drug, FDA Nod For Regeneron's Ebola Treatment, Can Fite Issues Psoriasis Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14)
Benzinga · 10/15 12:03
SpringWorks Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
STAMFORD, Conn., Oct. 13, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today the closing of its underwritten public offering of 5,637,254 shares of its common stock at a public offering price of $51.00 per share, before underwriting discounts and commissions, which includes the exercise in full by the underwriters of their option to purchase up to an additional 735,294 shares of common stock in this offering. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $287.5 million. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Wedbush Securities Inc. acted as co-manager for the offering.An automatic shelf registration statement on Form S-3ASR (including a prospectus) relating to these securities was filed with the Securities and Exchange Commission (SEC) and has become effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.The offering was made only by means of a prospectus and prospectus supplement that form part of the automatic shelf registration statement. A copy of the final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1115 Long Island Avenue, Edgewood, NY 11717, by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; Goldman Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526 or by emailing prospectus-ny@ny.email.gs.com or Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY,11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by emailing PostSaleManualRequests@broadridge.com.About SpringWorks TherapeuticsSpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding SpringWorks’ expectations with respect to the completion of the proposed public offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, and other risks identified in the section entitled “Risk Factors” in Item 1A of Part II of SpringWorks’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, as well as discussions of potential risks, uncertainties and other important factors in SpringWorks’ subsequent filings with the Securities and Exchange Commission. SpringWorks cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. SpringWorks disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent SpringWorks’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.ContactKim Diamond Phone: 203-561-1646 Email: kdiamond@springworkstx.com
GlobeNewswire · 10/13 20:05
The Daily Biotech Pulse: J&J Pauses Coronavirus Vaccine Studies, Voyager's Huntington's Disease Study Placed On Hold, Altimmune Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12)
Benzinga · 10/13 12:20
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SWTX. Analyze the recent business situations of SPRINGWORKS THERAPEUTICS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SWTX stock price target is 70.00 with a high estimate of 76.00 and a low estimate of 57.00.
EPS
Institutional Holdings
Institutions: 111
Institutional Holdings: 37.38M
% Owned: 76.65%
Shares Outstanding: 48.77M
TypeInstitutionsShares
Increased
27
2.54M
New
22
1.18M
Decreased
30
1.09M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.67%
Key Executives
Chairman/Executive Director/Independent Director
Daniel Lynch
Chief Executive Officer/Director/Primary Contact
Saqib Islam
Chief Financial Officer
Francis Perier
Senior Vice President
L. Mary Smith
General Counsel/Secretary
Herschel Weinstein
Other/Director
Stephen Squinto
Other
Badreddin Edris
Other
Jens Renstrup
Independent Director
Alan Fuhrman
Independent Director
Freda Lewis-Hall
Independent Director
Jeffrey Schwartz
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SWTX
SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing medicines for patient suffering from rare diseases and cancer. The Company has a portfolio of small molecule targeted oncology product candidates and other programs addressing genetically defined cancers. Its provides Nirogacestat, which is an oral, small molecule gamma secretase inhibitor (GSI). Nirogacestat is in development for the treatment of desmoid tumors. It also provides Mirdametinib, which is an oral, small molecule MEK inhibitor. Mirdametinib is in development for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). BGB-3245 is an investigational oral, selective small molecule inhibitor of specific BRAF driver mutations and genetic fusions. Nirogacestat is in the Phase III DeFi clinical trial for the treatment of desmoid tumors.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of SpringWorks Therapeutics Inc stock information, including NASDAQ:SWTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SWTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SWTX stock methods without spending real money on the virtual paper trading platform.